The FDA has approved a new drug named Ozanimod for the treatment of multiple sclerosis. Ozanimod binds to receptors in lymphocytes' surfaces, preventing them from reaching the brain. As the number of active lymphocytes decreases, the attack on the immune system diminishes.
from Neuroscience News https://ift.tt/2yhpHqH
from Neuroscience News https://ift.tt/2yhpHqH
Comments
Post a Comment